ForumIAS LATEST
- SFG FRC 2027 | Program starts from 19th Dec. 2026 | Admissions open for Entrance Test Click Here to know more →
- Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
- [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 10th October onwards Click Here to Read More →
- 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 11th Oct. Click Here to Read More →
- The Central Drugs Standard Control Organisation (CDSCO, the apex drug regulator, has asked drug manufacturers to inform consumers about known side effects/ adverse reactions after intake of certain popular antibiotics. These antibiotics include Cefotaxime, Ofloxacin Cefixime, Tranexamic Acid, Quetiapine, Sulfasalazine and Sodium Valproate.
- CDSCO’s move has come after the National Co-ordination Centre of the Pharmacovigilance Programme of India (PvPI) had alerted the Union Health Ministry about adverse side-effects of these antibiotics.
- In 2010, the Pharmacovigilance Programme of India (PvPI) was started by the Indian government with All India Institute of Medical Sciences (AIIMS), New Delhi as the National Coordination Centre. The aim is to monitor Adverse Drug Reactions (ADRs) in India for safe-guarding public health. In 2011, the National Coordination Centre was shifted from AIIMS, New Delhi to the Indian Pharmacopoeia Commission, Ghaziabad, Uttar Pradesh.
- The Indian Pharmacopoeia Commission (IPC) is an autonomous institution under the Ministry of Health and Family Welfare which is responsible to set standards of drugs manufactured, sold and consumed in India.
